Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6305631 | 0.86 | EZH2 (0.41) | L3MBTL1MAPTKDM4ERAB9ANPC1 | |
| SCHEMBL6303213 | 0.83 | EZH2 (0.56) | EZH2MAPK14MMP2MMP7MMP9 | |
| SCHEMBL7115042 | 0.83 | L3MBTL1 (0.41) | L3MBTL1MAPTKDM4EMAPK8PDE10A | |
| SCHEMBL6305897 | 0.83 | L3MBTL1 (0.41) | L3MBTL1MAPTKDM4EMAPK8PDE10A | |
| SCHEMBL6304573 | 0.82 | MMP2 (0.47) | MAPTRAB9ANPC1EZH2MAPK14 | |
| SCHEMBL6303016 | 0.82 | KCNQ3 (0.48) | RAB9ANPC1EZH2ALDH1A1MMP2 | |
| SCHEMBL6310508 | 0.82 | TAS1R3 (0.40) | EZH2MAPK14PPARGMMP2MMP7 | |
| SCHEMBL6303505 | 0.82 | MAPK14 (0.45) | RAB9ANPC1EZH2MAPK14MMP2 | |
| SCHEMBL6310966 | 0.81 | MAPK14 (0.44) | RAB9ANPC1EZH2MAPK14MMP2 | |
| SCHEMBL6310134 | 0.81 | LOXL2 (0.41) | RAB9ANPC1EZH2MAPK14PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | NAT1, CYP7A1, CYP7B1 | L3MBTL1 2491/4885MAPT 2109/4885KDM4E 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.